Video
The inflammatory basis of pulmonary arterial hypertension Editor-in-Chief: Kazuomi Kario Department of Medicine School xnd Medicine Jichi Citrus aurantium for cognitive health University Inflwmmation Japan. ISSN Inflammatoon : ISSN Online : All-natural products DOI: High blood pressure Hypertension and inflammation are Hypertension and inflammation with increases in circulating levels of inflammation markers which can reflect vascular inflammatory processes, suggesting that hypertension is a low-grade inflammatory process. The vascular inflammation associated with hypertension could be the link between high blood pressure levels and the atherosclerotic process, which is the principal origin of cardiovascular disease, the leading cause of worldwide mortality.Hypertension and inflammation -
Variants of this gene are linked to autoimmune diseases such as multiple sclerosis, coeliac disease, and type 1 diabetes. All regulated genes are expressed in leucocytes.
Clinically available immunomodulatory drugs employ heterogeneous mechanisms of action, and hence their impact on BP regulatory systems is likely to be diverse.
Agents reviewed below are selected to illustrate this breadth. Using a systematized search, we identified 20 studies reporting BP in patients prescribed adalimumab, infliximab, etanercept, golimumab, and six papers with a mix of TNF-α inhibitors used see Table 2.
Study populations included those with RA, ankylosing spondylitis, psoriasis, and combined rheumatological diseases. Follow-up was from 2 weeks to 12 months and cohort sizes varied from 9 to Five randomized trials with placebo or other pharmacotherapy comparators produce a combined estimate of 4.
Only two studies used the gold standard of ambulatory BP monitoring ABPM , Yoshida et al. In contrast Grossman et al. Elevated BP was not an inclusion criterion in any of the studies and hypertension was reported inconsistently.
Two of the studies reported only mean arterial pressure, , six studies did not report prevalence or use of anti-hypertensives, , , , , , and one specified no anti-hypertensive use. Observational data on incident rates of hypertension offer additional insight. In comparison with non-biologic anti-inflammatory medications, anti-TNF-α initiators demonstrated no difference in crude or adjusted rates of incident hypertension HR: 0.
Meta-analysis and Forest Plot using random effect model, of TNF-α inhibitor studies reporting SBP outcomes, with reference to average baseline SBP, population size, and study weighting.
Panel A includes cohort studies reporting average SBP prior and subsequent to drug initiation; panel B includes randomized trials with comparison to placebo or other pharmacotherapy. ADL, adalimumab; ETN, etanercept; GOL, golimumab; IFX, infliximab; Mixed, different TNF-α inhibitors within the study; SBP, systolic blood pressure; sDMARD, conventional synthetic disease modifying anti-rheumatic; TNF-α, tumour necrosis factor alpha.
Human studies pertaining to TNF-α inhibitor use and reporting data on BP outcomes. ADL, Adalimumab, ank spod, ankylosing spondylitis; IFX, infliximab; ETN, etanercept; GOL, golimumab; MAP, mean arterial pressure; PsA, psoriatic arthritis; RA, rheumatoid arthritis.
placebo for a composite end point of myocardial infarction, stroke, or cardiovascular death. Largest effect size was in the quartile demonstrating greatest high-sensitivity C-reactive protein and IL-6 reductions.
Considering other cytokine inhibitor approaches, we focused on pharmacotherapies with both animal study evidence and use in clinical practice: secukinumab and tocilizumab.
Despite BP being the primary outcome, this trial reported no change at 1 year, though patients were not hypertensive at baseline.
Three papers were identified reporting BP data with IL-6 antagonist tocilizumab, two used in combination with methotrexate MTX. Overall, the minimally available evidence detailed in Supplementary material online, Table does not support an association with BP lowering.
Mycophenolate mofetil MMF inhibits nucleotide synthesis and thus prevents lymphocyte proliferation. In an early study, Herrera et al. Notably, BP increased following MMF cessation in this study. The authors also demonstrated a reduction in urinary TNF-α was during MMF therapy.
Ninety percent of these subjects had hypertension at baseline. Bubble plot illustrating immunomodulatory agents plotted by baseline SBP x -axis and average change in SBP y -axis , both in mmHg, with bubble area representing cohort size.
CNI, calcineurin inhibitor; CTLA4-Ig, cytotoxic T-lymphocyte-associated protein 4 immunoglobulin; HCQ, hydroxychloroquine; IL, interleukin; MMF, mycophenolate mofetil; mTOR: mammalian target of rapamycin; MTX: methotrexate; SBP, systolic blood pressure; TNF, tumour necrosis factor.
MTX is a chemotherapy agent and disease-modifying anti-rheumatic drug DMARD. Five studies involving between 20 and participants were identified, reporting average baseline SBP between and Only one of these employed ABPM. Average SBP lowering ranged from 1. Hydroxychloroquine is an antimalarial agent that is used as a DMARD, and experimentally in IgA nephropathy.
The largest of these involved patients with RA and showed that hydroxychloroquine lowered BP by 1. Leflunomide is a pyrimidine synthesis inhibitor used in active RA and psoriatic arthritis.
Calcineurin inhibitors CNIs block the earliest steps of T cell activation, but also have substantial off-target effects, including stimulation of endothelin production, increases in sympathetic outflow, renal vasoconstriction, salt retention, and hypertension Figure 4. In four of these, the baseline BP was in the hypertensive range.
Renal and immune system effects of calcineurin inhibitors influencing blood pressure. COX2, cyclooxygenase-2; GFR, glomerulofiltration rate; IL-2, interleukin-2; NFAT, nuclear factor of activated T cells; NO, nitric oxide; TMA, thrombotic microangiopathy; RAAS, renin—angiotensin—aldosterone system; ROS, reactive oxygen species; SNS, sympathetic nervous system; TGF-β, transforming growth factor beta.
Created in BioRender. Mammalian target of rapamycin mTOR inhibitors such as sirolimus and everolimus regulate cellular metabolism, growth, and proliferation, offering alternative immunosuppression following transplantation.
This was dominated by reduction in nocturnal SBP in both the everolimus and cyclosporine arms. Abatacept is composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of cytotoxic T-lymphocyte-associated protein 4 CTLA This agent targets T cell co-stimulation and is commonly used in transplant and rheumatologic diseases.
In five studies of RA patients reporting BP outcomes with abatacept, specific values were not available for two and none of the others reported a statistically significant effect on BP. All of these were in transplant recipients and were compared to patients receiving CNIs.
Two of these studies involved cross over from CNI to Belatacept and showed a SBP reduction of 5. One RCT reported no difference in mean SBP. The apparent BP benefit with belatacept but not abatacept likely reflects population differences transplant vs. RA, respectively , potential physiological changes post-transplantation, and the cross-over effect from CNI, which as noted above, has off-target effects that can raise BP.
Rituximab is a monoclonal antibody against CD20, resulting in B cell apoptosis and depletion. It is used in lymphoid and blood malignancies and diverse autoimmune diseases. Trials reporting BP that are not confounded by polypharmacy were sparse. In summary, trials in rheumatic, autoimmune, and transplant patients indicate a possible BP-lowering effect of selected anti-inflammatory therapies targeting diverse pathways previously identified by pre-clinical studies.
The evidence appears to be most consistent in relation to anti-TNF-α agents, while other therapies such as hydroxychloroquine, MMF, and mTORs all suggest BP-lowering effect Figures 3 and 5. Data are however conflicting, and hypertension was rarely a pre-specified outcome measure. Trials often involved normotensive populations in which BP lowering is difficult to observe.
A combined analysis of studies discussed in this paper shows that cohorts with higher average baseline SBP appear to achieve greater BP-lowering effect Figure 3 , an association also reported for anti-hypertensive drugs.
Immunomodulatory drugs and the level of animal and clinical evidence available regarding blood pressure and organ system outcomes. Summarized according to the aggregated weight of the available evidence. BP, blood pressure; CD, cluster of differentiation; CNI, calcineurin inhibitor; CTLA4-Ig, cytotoxic T-lymphocyte-associated protein 4 immunoglobulin; HCQ, hydroxychloroquine; IL, interleukin; MMF, mycophenolate mofetil; mTOR: mammalian target of rapamycin; MTX: methotrexate; TNF, tumour necrosis factor.
Includes chronic kidney disease, end-stage kidney disease, fibrosis, and inflammation. Several non - pharmacological treatment approaches have shown beneficial effects in reducing inflammation and therefore improving patient outcomes in the context of hypertension.
Animal studies suggest that periodontal Porphyromonas gingivalis infection increases IFN-γ and TNF-α production through modulation of Th1 responses, leading to BP elevation, endothelial dysfunction, and vascular inflammation.
As in the case of pharmacological interventions, BP reductions were not observed in normotensive individuals.
For dietary interventions, most research has focused on CVD risk reduction, though BP lowering has also been demonstrated in both normotensive and hypertensive cohorts, , at least in part immune-mediated via effects of diet on the microbiome.
Dietary salt is another dominant driver of hypertension, primarily through activation of renin—angiotensin—aldosterone system ; at higher concentration, salt also favours pro-inflammatory monocyte and T cell phenotypes with increased tissue infiltration and microvascular dysfunction.
The central nervous system regulates vascular and kidney function through sympathetic innervation but is also a potent modulator of immune responses. Animal and human studies demonstrate the role of neuroimmune axis in the pathogenesis of hypertension, , with murine renal denervation RDN inducing a reduction in BP, — and reduction in renal inflammation, T cell activation, and pro-inflammatory cytokine production.
One trial demonstrated reductions in TNF-α and IL-1β, and up-regulation of IL one day after RDN; however, this did not persist to day 3, and was not corroborated elsewhere. An alternative approach to sympathetic denervation is augmentation of parasympathetic activity through vagus nerve stimulation VNS.
This approach has proven effective in hypertensive rodent models. Hypertension-mediated organ damage HMOD correlates with BP values in hypertension , ; however, genetics, lifestyle, and co-morbid conditions may also contribute to end-organ damage independently of BP levels.
Similarly, the target organ benefit of immunomodulation might be partially independent of BP effects. The strength of evidence regarding the effects of immunomodulatory therapy on HMOD in experimental and clinical settings is summarized in Figure 5.
This study reported a reduction in cardiovascular risk in response to numerous immunomodulatory drugs, including biologic agents HR: 0. Nurmohamed et al. reviewed 90 studies reporting cardiovascular risk outcomes in rheumatological conditions treated with abatacept, TNF-α inhibitors, rituximab, secukinumab, tocilizumab, and tofacitinib.
They report a neutral effect on BP, on surrogate markers of cardiovascular risk, and on MACE, though authors emphasise the variation in quantity and quality of evidence. Colchicine is hypothesized to inhibit microtubular polymerization, assembly of the NLRP3 inflammasome, and IL-1β and IL production.
In acute coronary syndrome, colchicine abrogates local increases in IL-1β, IL, and IL-6 levels, and its addition to aspirin and statin reduces high-sensitivity C-reactive protein. Similarly, LoDoCo2 randomized chronic coronary disease patients to low-dose colchicine, with composite end-point events in 6.
Overall, we would conclude that there is evidence of improvement in MACE for TNF-α inhibitors, MTX, tocilizumab, secukinumab, leflunomide and colchicine, though heterogeneity of study designs and outcomes limits the strength of this statement, and we have not explored the relationship between reduction in inflammation and MACE suggested by CANTOS and TNF-α inhibitor responders in the registry data above.
HMOD outcomes beyond MACE are surmised in Figure 5 for common immunomodulatory drugs. While experimental, genetic, and clinical evidence supports the role of inflammation and immune system involvement in hypertension and associated vascular, renal, and cardiac pathology, immunomodulatory approaches are not currently considered therapeutic options in BP lowering and cardiovascular disease reduction.
Indeed, clinical evidence reviewed in this paper shown a highly heterogeneous effect of immune targeting on BP and cardiovascular events across a wide range of patients mainly with various underlying immune-mediated diseases.
Going forward, there are several important considerations. As is the case with traditional anti-hypertensive medications, the BP-lowering effects of anti-inflammatory agents appear to be limited to those with uncontrolled hypertension.
This is not surprising as numerous compensatory mechanisms make lowering beyond normal BP difficult. It is also important to consider that the effects may be limited to patients with active pro-hypertensive inflammatory mechanisms.
The lesson from CIRT, TNF-α inhibitor responders vs. non-responders, CANTOS, and the body of the evidence presented is that there must be active inflammation.
Secondly, we must target the optimal checkpoint in the inflammation—hypertension relationship to optimize benefit without adverse effect, and so far, this has remained elusive at a population level.
Finally, it is important to consider that virtually all of the preclinical studies investigating the anti-hypertensive effect of immune interventions on hypertension have involved treatment of animals at the onset on hypertension, often concomitantly with the onset of the disease.
In contrast, these agents are usually given to humans with long-standing hypertension. It is possible, and even likely that once hypertension has been established, there are chronic changes in renal and vascular function and structure that render such treatment less effective.
In this regard, treatment of younger individuals with early onset hypertension might yield different results than those observed in the studies summarized here.
Supplementary material is available at Cardiovascular Research online. Data derived from sources in the public domain. Reference details are provided in full. Statistical assistance was provided by Dr John McClure, University of Glasgow.
Software used in the generating of this manuscript includes BioRender. com figures , Minitab Statistical Software, and Meta-essentials meta-analysis. Tomasz Guzik and Pasquale Maffia have positions within CVR; the manuscript was handled by a consulting editor.
Libby P. The changing landscape of atherosclerosis. Nature ; : — Google Scholar. Liberale L , Montecucco F , Tardif JC , Libby P , Camici GG. Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease.
Eur Heart J ; 41 : — Nus M , Mallat Z , Sage A. Beating T-lymphocyte driven atherosclerosis with B- and T-lymphocyte attenuator. Cardiovasc Res ; : — van Kuijk K , Kuppe C , Betsholtz C , Vanlandewijck M , Kramann R , Sluimer JC. Heterogeneity and plasticity in healthy and atherosclerotic vasculature explored by single-cell sequencing.
Douna H , Amersfoort J , Schaftenaar FH , Kröner MJ , Kiss MG , Slütter B , Depuydt MAC , Bernabé Kleijn MNA , Wezel A , Smeets HJ , Yagita H , Binder CJ , Bot I , van Puijvelde GHM , Kuiper J , Foks AC. B- and T-lymphocyte attenuator stimulation protects against atherosclerosis by regulating follicular B cells.
Visseren FLJ , Mach F , Smulders YM , Carballo D , Koskinas KC , Bäck M , Benetos A , Biffi A , Boavida J-M , Capodanno D , Cosyns B , Crawford C , Davos CH , Desormais I , Di Angelantonio E , Franco OH , Halvorsen S , Hobbs FDR , Hollander M , Jankowska EA , Michal M , Sacco S , Sattar N , Tokgozoglu L , Tonstad S , Tsioufis KP , van Dis I , van Gelder IC , Wanner C , Williams B.
Eur Heart J ; 42 : — Steffens S , van LS , Sluijter JPG , Tocchetti CG , Thum T , Madonna R. Stimulating pro-reparative immune responses to prevent adverse cardiac remodelling: consensus document from the joint meeting of the ESC Working Groups of cellular biology of the heart and myocardial function.
Elnabawi YA , Dey AK , Goyal A , Groenendyk JW , Chung JH , Belur AD , Rodante J , Harrington CL , Teague HL , Baumer Y , Keel A , Playford MP , Sandfort V , Chen MY , Lockshin B , Gelfand JM , Bluemke DA , Mehta NN.
Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Efficacy and safety of low-dose colchicine after myocardial infarction.
N Engl J Med ; : — Ridker PM , Everett BM , Thuren T , MacFadyen JG , Chang WH , Ballantyne C , Fonseca F , Nicolau J , Koenig W , Anker SD , Kastelein JJP , Cornel JH , Pais P , Pella D , Genest J , Cifkova R , Lorenzatti A , Forster T , Kobalava Z , Vida-Simiti L , Flather M , Shimokawa H , Ogawa H , Dellborg M , Rossi PRF , Troquay RPT , Libby P , Glynn RJ , Krum H , Varigos J.
Antiinflammatory therapy with canakinumab for atherosclerotic disease. Nidorf SM , Fiolet ATL , Mosterd A , Eikelboom JW , Schut A , Opstal TSJ , The SHK , Xu X-F , Ireland MA , Lenderink T , Latchem D , Hoogslag P , Jerzewski A , Nierop P , Whelan A , Hendriks R , Swart H , Schaap J , Kuijper AFM , van Hessen MWJ , Saklani P , Tan I , Thompson AG , Morton A , Judkins C , Bax WA , Dirksen M , Alings M , Hankey GJ , Budgeon CA , Tijssen JGP , Cornel JH , Thompson PL ; LoDoCo2 Trial Investigators.
Colchicine in patients with chronic coronary disease. Weber BN , Blankstein R. Something old, something new: a paradigm for considering immune therapies for cardiovascular disease. Cardiovasc Res ; : e51 — e GBD Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for countries and territories, — a systematic analysis for the Global Burden of Disease Study Lancet ; : — Markó L , Park J-K , Henke N , Rong S , Balogh A , Klamer S , Bartolomaeus H , Wilck N , Ruland J , Forslund SK , Luft FC , Dechend R , Müller DN.
Grabie N , Lichtman AH , Padera R. T cell checkpoint regulators in the heart. Peet C , Ivetic A , Bromage DI , Shah AM. Cardiac monocytes and macrophages after myocardial infarction.
Drummond GR , Vinh A , Guzik TJ , Sobey CG. Immune mechanisms of hypertension. Nat Rev Immunol ; 19 : — Okuda T , Grollman A. Passive transfer of autoimmune induced hypertension in the rat by lymph node cells. Tex Rep Biol Med ; 25 : — Svendsen U.
The role of thymus for the development and prognosis of hypertension and hypertensive vascular disease in mice following renal infarction. Acta Pathol Microbiol Scand A ; 84 : — Svendsen UG.
Influence of neonatal thymectomy on blood pressure and hypertensive vascular diseases in rats with renal hypertension.
Acta Pathol Microbiol Scand A ; 83 : — Thymus dependency of periarteritis nodosa in DOCA and salt treated mice. Acta Pathol Microbiol Scand A ; 82 : 30 — Olsen F. Transfer of arterial hypertension by splenic cells from DOCA-salt hypertensive and renal hypertensive rats to normotensive recipients.
Acta Pathol Microbiol Scand C ; 88 : 1 — 6. Evidence for an immunological factor in the hypertensive vascular disease. Acta Pathol Microbiol Scand A ; 79 : 22 — Vinh A , Chen W , Blinder Y , Weiss D , Taylor WR , Goronzy JJ , Weyand CM , Harrison DG , Guzik TJ.
Circulation ; : — Guzik TJ , Hoch NE , Brown KA , McCann LA , Rahman A , Dikalov S , Goronzy J , Weyand C , Harrison DG. Role of the T cell in the genesis of angiotensin II—induced hypertension and vascular dysfunction.
J Exp Med ; : — Pollow DP , Uhrlaub J , Romero-Aleshire M , Sandberg K , Nikolich-Zugich J , Brooks HL , Hay M. Sex differences in T-lymphocyte tissue infiltration and development of angiotensin II hypertension. Hypertension ; 64 : — Seniuk A , Thiele JL , Stubbe A , Oser P , Rosendahl A , Bode M , Meyer-Schwesinger C , Wenzel UO , Ehmke H.
Rag1 Knockout mice generated at the Jackson Laboratory in show a robust wild-type hypertensive phenotype in response to Ang II angiotensin II. Hypertension ; 75 : — Ji H , Pai AV , West CA , Wu X , Speth RC , Sandberg K.
Hypertension ; 69 : — Mattson DL , Lund H , Guo C , Rudemiller N , Geurts AM , Jacob H. Genetic mutation of recombination activating gene 1 in Dahl salt-sensitive rats attenuates hypertension and renal damage.
Am J Physiol Regul Integr Comp Physiol ; : R — R Crowley SD , Song Y-S , Lin EE , Griffiths R , Kim H-S , Ruiz P. Lymphocyte responses exacerbate angiotensin II-dependent hypertension.
Am J Physiol Regul Integr Comp Physiol ; : — Wu J , Thabet SR , Kirabo A , Trott DW , Saleh MA , Xiao L , Madhur MS , Chen W , Harrison DG. Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-activated protein kinase. Circ Res ; : — Trott DW , Thabet SR , Kirabo A , Saleh MA , Itani H , Norlander AE , Wu J , Goldstein A , Arendshorst WJ , Madhur MS , Chen W , Li C-I , Shyr Y , Harrison DG.
Kvakan H , Kleinewietfeld M , Qadri F , Park J-K , Fischer R , Schwarz I , Rahn H-P , Plehm R , Wellner M , Elitok S , Gratze P , Dechend R , Luft FC , Muller DN. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Barhoumi T , Kasal DA , Li MW , Shbat L , Laurant P , Neves MF , Paradis P , Schiffrin EL.
T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension ; 57 : — Caillon A , Mian MOR , Fraulob-Aquino JC , Huo K-G , Barhoumi T , Ouerd S , Sinnaeve PR , Paradis P , Schiffrin EL. γδ T cells mediate angiotensin II-induced hypertension and vascular injury.
Wenzel P , Knorr M , Kossmann S , Stratmann J , Hausding M , Schuhmacher S , Karbach SH , Schwenk M , Yogev N , Schulz E , Oelze M , Grabbe S , Jonuleit H , Becker C , Daiber A , Waisman A , Münzel T. Lysozyme M-positive monocytes mediate angiotensin ii-induced arterial hypertension and vascular dysfunction.
Moore JP , Vinh A , Tuck KL , Sakkal S , Krishnan SM , Chan CT , Lieu M , Samuel CS , Diep H , Kemp-Harper BK , Tare M , Ricardo SD , Guzik TJ , Sobey CG , Drummond GR. M2 macrophage accumulation in the aortic wall during angiotensin II infusion in mice is associated with fibrosis, elastin loss and elevated blood pressure.
Am J Physiol Heart Circ Physiol ; : H — H De Ciuceis C , Amiri F , Brassard P , Endemann DH , Touyz RM , Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury.
Arterioscler Thromb Vasc Biol ; 25 : — Macrophage depletion lowered blood pressure and attenuated hypertensive renal injury and fibrosis. Front Physiol ; 9 : e Hevia D , Araos P , Prado C , Luppichini Rojas FE , Alzamora M , Cifuentes-Araneda R , Gonzalez F , Amador AA , Pacheco CA , Michea R.
Hypertension ; 71 : — Chan CT , Sobey CG , Lieu M , Ferens D , Kett MM , Diep H , Kim HA , Krishnan SM , Lewis CV , Salimova E , Tipping P , Vinh A , Samuel CS , Peter K , Guzik TJ , Kyaw TS , Toh BH , Bobik A , Drummond GR. Obligatory role for B cells in the development of angiotensin II-dependent hypertension.
Hypertension ; 66 : — Chen Y , Dale BL , Alexander MR , Xiao L , Ao M , Pandey AK , Smart CD , Davis GK , Madhur MS. Class switching and high-affinity immunoglobulin G production by B cells is dispensable for the development of hypertension in mice.
Kossmann S , Schwenk M , Hausding M , Karbach SH , Schmidgen MI , Brandt M , Knorr M , Hu H , Kröller-Schön S , Schönfelder T , Grabbe S , Oelze M , Daiber A , Münzel T , Becker C , Wenzel P. Angiotensin ii-induced vascular dysfunction depends on interferon-γ- driven immune cell recruitment and mutual activation of monocytes and NK-cells.
Arterioscler Thromb Vasc Biol ; 33 : — Rodríguez-Iturbe B , Ferrebuz A , Vanegas V , Quiroz Y , Mezzano S , Vaziri ND. Early and sustained inhibition of nuclear factor-kappaB prevents hypertension in spontaneously hypertensive rats.
J Pharmacol Exp Ther ; : e51 — e Brands MW , Banes-Berceli AKL , Inscho EW , Al-Azawi H , Allen AJ , Labazi H. Hypertension ; 56 : — NLRP3 inflammasome activation is involved in Ang II-induced kidney damage via mitochondrial dysfunction.
Oncotarget ; 7 : — Renal tumor necrosis factor α contributes to hypertension in Dahl salt-sensitive rats. Sci Rep ; 6 : McShane L , Tabas I , Lemke G , Kurowska-Stolarska M , Maffia P. TAM receptors in cardiovascular disease.
Nosalski R , Mikolajczyk T , Siedlinski M , Saju B , Koziol J , Maffia P , Guzik TJ. Pharmacol Res ; : MacRitchie N , Grassia G , Noonan J , Cole JE , Hughes CE , Schroeder J , Benson RA , Cochain C , Zernecke A , Guzik TJ , Garside P , Monaco C , Maffia P.
Kirabo A , Fontana V , de Faria APC , Loperena R , Galindo CL , Wu J , Bikineyeva AT , Dikalov S , Xiao L , Chen W , Saleh MA , Trott DW , Itani HA , Vinh A , Amarnath V , Amarnath K , Guzik TJ , Bernstein KE , Shen XZ , Shyr Y , Chen S-C , Mernaugh RL , Laffer CL , Elijovich F , Davies SS , Moreno H , Madhur MS , Roberts J , Harrison DG.
DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest ; : — Krishnan SM , Dowling JK , Ling YH , Diep H , Chan CT , Ferens D , Kett MM , Pinar A , Samuel CS , Vinh A , Arumugam TV , Hewitson TD , Kemp-Harper BK , Robertson AAB , Cooper MA , Latz E , Mansell A , Sobey CG , Drummond GR.
Br J Pharmacol ; : — Carnevale D , Perrotta M , Pallante F , Fardella V , Iacobucci R , Fardella S , Carnevale L , Carnevale R , De LM , Cifelli G , Lembo G. A cholinergic-sympathetic pathway primes immunity in hypertension and mediates brain-to-spleen communication.
Nat Commun ; 7 : Carnevale D , Pallante F , Fardella V , Fardella S , Iacobucci R , Federici M , Cifelli G , De Lucia M , Lembo G. The angiogenic factor PIGF mediates a neuroimmune interaction in the spleen to allow the onset of hypertension. Immunity ; 41 : — Rodriguez-Iturbe B , Lanaspa MA , Johnson RJ.
The role of autoimmune reactivity induced by heat shock protein 70 in the pathogenesis of essential hypertension. Idris-Khodja N , Mian MOR , Paradis P , Schiffrin EL.
Dual opposing roles of adaptive immunity in hypertension. Eur Heart J ; 35 : — Madhur MS , Kirabo A , Guzik TJ , Harrison DG. From rags to riches: moving beyond Rag1 in studies of hypertension. Xiao L , Harrison DG. Inflammation in hypertension. Can J Cardiol ; 36 : — Nosalski R , Siedlinski M , Denby L , McGinnigle E , Nowak M , Cat AND , Medina-Ruiz L , Cantini M , Skiba D , Wilk G , Osmenda G , Rodor J , Salmeron-Sanchez M , Graham G , Maffia P , Graham D , Baker AH , Guzik TJ.
T-cell-derived miRNA mediates perivascular fibrosis in hypertension. Hoyer FF , Nahrendorf M. This study demonstrated that B cells are crucial for the development of Ang II-induced hypertension [ 50 ].
Mutations in the BAFF-R are associated with B-cell lymphopenia and antibody deficiency. On contrary to the above mentioned study results one experimental study on mice reported that mice that received Treg cells and infused with Ang II showed similar incitement in blood pressure with group of mice that infused Ang II without receiving transfer of Treg cells [ 54 ].
The different results of the latter study may be due to differences in experiment procedures as all former studies performed Treg cells transfer few weeks before infusion of Ang II or aldosterone while the latter study performed Treg cells transfer and Ang II infusion simultaneously.
Thus, the existing body of knowledge clearly confirmed existence of association between immune system activation and hypertension while ascertaining the cause effect relationship between inflammation and hypertension needs further study. The maintenance of physiological blood pressure levels involves coordinated control and regulation from neurohormonal system which includes the renin-angiotensin-aldosterone system RAAS , the natriuretic peptides and the endothelium, the sympathetic nervous system SNS and the immune system on functions of the heart, blood vessels and the kidneys.
Perturbation in function of organs or systems that are involved in BP control can directly or indirectly lead to increase in blood pressure that ultimately ends up in the development of hypertension, and over time results in target organ damage such as, left ventricular hypertrophy and chronic kidney disease CKD and CVD outcomes [ 55 ].
Existing observational and experimental studies highlight that in some hypertensive patients at least, additional drivers of hypertension must exist than the already known mechanisms involved in pathophysiology of hypertension, and new targets must be defined [ 10 ].
Inflammation and immune system perturbation are likely contributors in the development and sustaining of hypertension. The current overarching hypothesis about inflammation and immune system involvement in pathophysiology of hypertension is that immune cells accumulation in blood vessels in particular, in the perivascular fat , kidneys, heart, and brain promote a chronic inflammatory response that disrupts the blood pressure-regulating functions of these organs, leading to hypertension [ 56 ].
Accordingly, inflammation and immune system activation cause derangement in kidneys, arteries, brain, and heart functions that consequently promote hypertension and end-organ damage [ 57 ].
In support of the above mentioned hypothesis, current studies indicated that known stimuli that raise blood pressure such as high-salt diet, Ang II, and DOCA-salt directly and indirectly activate immune system cells. Elevated blood pressure can stress tissue cells to the level that DAMPs released by tissues.
Moreover, hypertensive stimuli can directly activate immune cells and also cause formation of neoantigens in the tissues. As a result of released DAMPs, neoantigens, and direct immune cells activation by hypertension stimuli, activated immune cells are formed, target organs infiltrated by activated immune cells, and diverse inflammatory cytokines are released by the activated immune cells.
Eventually, the affected target organs, mainly the kidney, blood vessels, and sympathetic nervous system function are perturbed and this leads to further elevated blood pressure level and finally to hypertension.
Immune cells such as monocytes, macrophages, and dendritic cells DCs release pro-hypertensive cytokines that promote the BP elevation via actions in the vasculature augmenting vascular dysfunction , kidney increasing sodium retention , and stimulating sympathetic nervous system outflow [ 58 ].
Many studies implicated that in the kidney, inflammatory cells and their products contribute to blood pressure elevation at least in part by increasing renal sodium transport [ 59 ].
Genetic deletion of IL-6 in mice results in blunted hypertension in response to angiotensin II infusion [ 60 ]. Taken together, these studies suggest that IL-6 enhances renal tubule sodium reabsorption and elevates BP at least in part through up regulation of renal tubule ENaC.
IL-1 is a pro-inflammatory cytokine that plays a central role in both acute and chronic inflammation, acting as a primary inducer of the innate immune response. Studies indicated that type 1 IL-1 receptor IL-1R1 stimulation by IL-1 potentiates blood pressure elevation by suppressing nitric oxide NO -dependent sodium excretion in the kidney.
Nitric oxide is a potent driver of sodium excretion in the kidney that acts via cyclic guanosine monophosphate cGMP and phosphodiesterase two to limit Na-K-2Cl cotransporter NKCC2 activity in the medullary thick ascending limb. Thus, by relieving NO inhibitory effect on NKCC2, IL-1 enhances reabsorption of electrolytes by medullary thick ascending limb and enhances retention of sodium and water by kidney [ 39 ].
Interferon gamma IFN-γ is a proinflammatory cytokine produced by innate and adaptive immune cells, and T cell production of IFN-γ is increased in Ang II-induced hypertension and mice deficient in IFN-γ have a blunted blood pressure response to Ang II infusion. Experimental studies indicate that IFN-γ positively regulates sodium hydrogen exchanger 3 NHE3 in the proximal tubule, NKCC2 in medullary thick ascending limb, and NCC in the distal tubule.
Whether IFN-γ directly modulates these sodium transporters or acts through downstream mediators is unknown [ 62 ]. Mice model experimental studies and cell culture model studies showed that interleukin 17A up regulates NHE3 in proximal segment , NCC and ENaC in distal segment of renal tubules.
Moreover, studies implicated that interleukin 17A regulates renal sodium transporters through a serum and glucocorticoid regulated kinase 1 SGK1 dependent pathway [ 63 ]. Serum and glucocorticoid regulated kinase1 is an important mediator of salt and water retention in the kidney through inhibition of neural precursor cell expressed developmentally down-regulated Nedd mediated ubiquitination and degradation of NHE3, NCC, and ENaC in the renal tubule, thereby enhancing the expression of these transporters on the cell surface [ 64 ].
Besides its effect on electrolyte and water homeostasis regulation function of kidney, sustained inflammation results in renal fibrosis, oxidative stress, glomerular injury, and chronic kidney disease [ 59 ]. Blood vessels are other organs that are affected by activated immune system and chronic low grade inflammation associated with hypertension.
Elevated blood pressure has an impact on the vasculature as a consequence of both the mechanical effects of blood pressure and shear stress [ 65 ]. Inflammation can impair blood vessels in two ways. Inflammation can cause functional arterial stiffening by impairing the functional relaxation capability of arteries.
The other mechanism is structural remodeling of arteries due to hypertension-associated inflammation [ 66 ]. Likewise, many experimental studies confirmed involvement of immune cells and inflammatory cytokines in vascular dysfunction associated with experimental hypertension.
An experimental study done on mice showed that Ang II infusion in mice increased immune cell content T cells, macrophages, and dendritic cells in perivascular adipose tissue and adventitia [ 67 ].
Endothelial cell culture study showed that inflammatory marker, C-reactive protein CRP , caused a marked down regulation of endothelial nitric oxide synthase eNOS mRNA and protein expression [ 68 ].
Similarly, TNF-α mediated inhibition of eNOS expression was observed in endothelial cell culture [ 69 ]. Acute treatment of endothelial cells with IL caused a significant increase in phosphorylation of the inhibitory eNOS residue threonine eNOS Thr [ 70 ]. All these studies indicate that inflammation decreases bioavailability of endothelial NO and thus impairs vascular smooth muscle relaxation and subsequent vasodilatations.
Moreover, involvement of immune cells and inflammatory cytokines in hypertensive vascular remodeling is implicated by many studies.
These studies implicated that immune cells and inflammatory cytokines play roles in vascular fibrosis, remodeling of small and large vessels, and vascular rarefaction in hypertension. Nonetheless, this remains to be further investigated. Other important organ both in development of hypertension and as an end-organ target of hypertension is the brain.
Regulation of short-term blood pressure level by sympathetic nervous system SNS is well established. SNS stimulation is associated with constriction of blood vessels, increased cardiac output, and augmented sodium and fluid retention by the kidneys [ 72 ].
Moreover, SNS serves as an integrative interface between the brain and the immune system. Mounting evidence implicate that many forms of essential hypertension are initiated and maintained by an elevated sympathetic tone [ 73 ].
The elevated sympathetic activity can be initiated by several factors including humoral factors such as angiotensin II and by environmental factors such as stress and high salt intake.
Observations such as increased splenic sympathetic nerve discharge SND and consequent increase in splenic cytokine gene expression IL-1β, IL-6, IL-2, and IL due to central Ang II administration the effect which was abrogated by splenic sympathetic denervation , and others led to the hypothesis that central stimuli such as angiotensin II cause modest elevations of blood pressure, which leads to activation of immune system.
Subsequently, the activated immune system leads to severe hypertension [ 76 ]. This hypothesis proposed a mechanism that occurs in a two-phase feed forward fashion. The initial phase brings a modest elevation in blood pressure i. In the second phase, the activated immune system generates cytokines and other inflammatory mediators which work in concert with the direct effects of hypertensive stimuli such as angiotensin II, catecholamines, and salt to cause vascular and renal dysfunction, promote vasoconstriction, vascular remodeling, a shift in the pressure-natriuresis curve and sodium retention, and ultimately causes sustained hypertension [ 74 ].
Hypertension is a widely prevalent public health problem of world adult population. It is a major risk factor of cardiovascular diseases, chronic kidney disease, and dementia. This indicates lack of efficacy of existing hypertension treatment strategies and existence of additional drivers of hypertension that must be identified and may be targeted.
One of the proposed pathophysiologic mechanisms that contribute for elevated BP and target organ damage among hypertensive patients is activation of the immune system and chronic low grade systemic inflammation.
In kidneys, inflammatory cells and their products contribute to blood pressure elevation by increasing renal sodium retention and by causing renal fibrosis, oxidative stress, and glomerular injury. IL-1, IL-6, IFN-γ, and IL are among pro-inflammatory cytokines that enhance sodium retention by renal tubules.
Activated immune cells and pro-inflammatory cytokines may contribute to functional arterial stiffening and structural remodeling of arteries that consequently cause elevated blood pressure in hypertension. C-reactive protein, TNF-α, and IL may hamper synthesis of or inhibit nitric oxide NO synthase.
Inflammatory cells that infiltrate blood vessels such as macrophages and lymphocytes and their pro-inflammatory products may also contribute for vascular remodeling. Perturbed immune system and chronic low grade systemic inflammation also enhance SNS activity which in turn contributes to elevated blood pressure by its effect on blood vessels tone vasoconstriction , on the kidneys sodium and water retention, RAAS activation and on immune system activation of immune system and enhanced production pro-inflammatory cytokines.
Thus, unraveling the detail pathophysiological mechanisms by which activated immune system and inflammation contribute to hypertension paves a way to identify target, and to design and develop therapeutic intervention for hypertension.
Even though currently there is no anti-inflammatory drug to treat hypertension, anti-inflammatory agents that target specific inflammatory pathway without compromising general immune system of an individual are possible future hypertension treatment drugs.
Author does not have any conflict of interest whatsoever with regard to content or opinions expressed above. Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3. Edited by Naofumi Shiomi. Open access peer-reviewed chapter Immune System and Inflammation in Hypertension Written By Mohammed Ibrahim Sadik.
DOWNLOAD FOR FREE Share Cite Cite this chapter There are two ways to cite this chapter:. Choose citation style Select style Vancouver APA Harvard IEEE MLA Chicago Copy to clipboard Get citation.
Choose citation style Select format Bibtex RIS Download citation. IntechOpen Lifestyle-Related Diseases and Metabolic Syndrome Edited by Naofumi Shiomi.
From the Edited Volume Lifestyle-Related Diseases and Metabolic Syndrome Edited by Naofumi Shiomi Book Details Order Print. Chapter metrics overview Chapter Downloads View Full Metrics.
Impact of this chapter. Abstract Hypertension is a widely prevalent and a major modifiable risk factor for cardiovascular diseases.
Keywords hypertension immune system inflammation. References 1. Williams B, Mancia G, Spiering W, Agabiti RE, Azizi M, Burnier M, et al.
European Heart Journal. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Stanaway JD, Afshin A, Gakidou E, Lim SS, Abate D, Abate KH, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for countries and territories, A systematic analysis for the Global Burden of Disease Study.
The Lancet. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries.
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison HC, et al.
Journal of the American College of Cardiology. Geldsetzer P, Manne GJ, Marcus ME, Ebert C, Zhumadilov Z, Wesseh CS, et al. The state of hypertension care in 44 low-income and middle-income countries: A cross-sectional study of nationally representative individual-level data from 1.
Wenzel UO, Ehmke H, Bode M. Immune mechanisms in arterial hypertension. Recent advances. Cell and Tissue Research. Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension.
BioMed Research International. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs.
Meizlish ML, Franklin RA, Zhou X, Medzhitov R. Tissue homeostasis and inflammation. Annual Review of Immunology. Chovatiya R, Medzhitov R.
Stress, inflammation, and defense of homeostasis. Molecular Cell. Medzhitov R. Origin and physiological roles of inflammation. Parkin J, Cohen B. An overview of the immune system. Marshall JS, Warrington R, Watson W, Kim HL. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension.
J Clin Invest. Peng H. Liao J. Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IkappaBalpha. J Biol Chem.
Libby P. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B.
Botting C. Panico M. Morris H. Hay R. Inhibition of NF-kappaB DNA binding by nitric oxide. Nucleic Acids Res. As mentioned in the introductory section, inflammation involves a coordinated interaction between the vessel wall, particularly the endothelium, and circulating immune cells.
An early event is rolling of leukocytes on the endothelium, mediated by the interaction of vascular selectins, including E-selectin and P-selectin, with leukocyte glycoprotein ligands like P-selectin glycoprotein ligand-1 and E-selectin ligand This is followed by interaction of cell adhesion molecules CAMs including the intracellular adhesion molecules ICAMs and the vascular CAM 1 VCAM-1 with leukocyte integrins including the lymphocyte function-associated antigen 1 and the very late antigen 4.
CAMs are produced not only by endothelial cells, but also by pericytes and vascular smooth muscle cells. The interaction of selectins and CAMs with their ligand is often accompanied by diverse intracellular signalling events in the vascular cell and the leukocyte.
A summary of these events is provided in Figure 1. Figure 1 Endothelial leukocyte interactions. In response to a variety of stimuli, including reactive oxygen species ROS , inflammatory cytokines, mechanical forces, and catecholamines, endothelial cells express increased levels of chemokines, selectins, and adhesion molecules, including the intracellular adhesion molecule ICAM 1 and the vascular cell adhesion molecule VCAM 1.
Monocytes possess ligands, including very late antigen 4 VLA4 , the leukocyte functional antigen 1 LFA1 and the macrophage antigen 1 MAC1 that bind to these receptors and promote initially rolling, then adhesion, and ultimately transmigration.
VLA4 undergoes a transformational change that enhances its ability to interact with VCAM Transmigrated monocytes can transform to inflammatory macrophages, monocyte-derived dendritic cells, or can exist in a minimally differentiated but activated state and can re-emerge as activated circulating monocytes.
Resident macrophages and dendritic cells are also present in the interstitium of tissues and have major roles in tissue repair and immune surveillance.
Chemokines are a subset of cytokines that avidly attract leukocytes. There are 4 classes of chemokines, including the CC chemokines that have 2 adjacent cysteines near their amino terminus, the CXC chemokines that have 2 cysteines separated by 1 amino acid at the amino terminus, the C chemokines that have 1 cysteine at the amino terminus, and the CX3C chemokine fractalkine that has 3 amino acids between the 2 amino-terminal cysteines.
Chemokines signal through their binding to 7 transmembrane-spanning receptors and also interact with endothelial glycosaminoglycans. Handel T. Proudfoot A. Leukocyte adhesion: reconceptualizing chemokine presentation by glycosaminoglycans.
Trends Immunol. Abstract Full Text Full Text PDF PubMed Scopus 73 Google Scholar. Ley K. Zarbock A. Neutrophil recruitment: from model systems to tissue-specific patterns. Abstract Full Text Full Text PDF PubMed Scopus 76 Google Scholar.
Hoskins Green H. Hart S. L-selectin: a major regulator of leukocyte adhesion, migration and signaling. Front Immunol. Kim M. LFA-1 in T cell migration and differentiation. Kim Y. Jang J. Lee S. Emerging roles of vascular cell adhesion molecule-1 VCAM-1 in immunological disorders and cancer.
Int J Mol Sci. Several factors governing leukocyte adhesion and trafficking seem to be affected by hypertension and likely play a role in this disease.
Liu et al. showed that ang II-induced hypertension was associated with an increase in vascular ICAM-1 expression, and that this was attenuated by inhibiting the NADPH oxidase. Yang F. Yang X. Jankowski M. Pagano P. NAD P H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy.
Arterioscler Thromb Vasc Biol. Bai J. Zhang Y. Blockade of intercellular adhesion molecule-1 prevents angiotensin II-induced hypertension and vascular dysfunction. Lab Invest.
Crossref PubMed Scopus 35 Google Scholar. Van Beusecum J. Itani H. Hypertension and increased endothelial mechanical stretch promote monocyte differentiation and activation: roles of STAT3, interleukin 6 and hydrogen peroxide. Cardiovasc Res. The endothelial expression of VCAM-1 is stimulated by ROS and altered mechanical forces and is inhibited by NO.
Olbrych M. Alexander R. Medford R. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells.
Proc Natl Acad Sci U S A. Guo W. Correlation of VCAM-1 expression in serum, cord blood, and placental tissue with gestational hypertension associated with fetal growth restriction in women from Xingtai Hebei, China. Genet Mol Res. Crossref Scopus 4 Google Scholar. Mircea P. Bala C. Intercellular adhesion molecule-1 ICAM-1 associates with hour ambulatory blood pressure variability in type 2 diabetes and controls.
Crossref PubMed Scopus 15 Google Scholar. Sklar L. Aspects of VLA-4 and LFA-1 regulation that may contribute to rolling and firm adhesion. Crossref PubMed Scopus 49 Google Scholar. Brand K. Schipek K. Adhesion of monocyte very late antigen-4 to endothelial vascular cell adhesion molecule-1 induces interleukin-1beta-dependent expression of interleukin-6 in endothelial cells.
Crossref PubMed Scopus 27 Google Scholar. Hafezi-Moghadam A. Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions.
As mentioned, chemokines and their receptors play major roles in leukocyte trafficking in inflammation. Their role in hypertension recently has been reviewed in depth. The role of chemokines in hypertension and consequent target organ damage.
Pharmacol Res. Crossref PubMed Scopus 47 Google Scholar. Quatraro C. Frassanito M. Silvestris F. Deregulated expression of monocyte chemoattractant protein-1 MCP-1 in arterial hypertension: role in endothelial inflammation and atheromasia. J Hypertens.
Crossref PubMed Scopus 41 Google Scholar. Hiasa K. Zhao Q. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling.
Liu Y. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Quigley J. Olearczyk J. Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension.
Crossref PubMed Scopus 63 Google Scholar. Warner G. Hartono S. Blockade of CCR2 reduces macrophage influx and development of chronic renal damage in murine renovascular hypertension.
Am J Physiol Renal Physiol. Crossref PubMed Scopus 33 Google Scholar. Osman M. Ferguson C. Ccl2 deficiency protects against chronic renal injury in murine renovascular hypertension. Sci Rep. Crossref PubMed Scopus 39 Google Scholar. Moore J. Budzyn K. Crossref PubMed Scopus 95 Google Scholar. Our group has studied the role of RANTES or CCL5 in hypertension, where it seems to have a predominant role in regulation of T-cell infiltration, particularly in the perivascular adipose tissue.
Nosalski R. Szczepaniak P. Role of chemokine RANTES in the regulation of perivascular inflammation, T-cell accumulation, and vascular dysfunction in hypertension. FASEB J. In general, CCR5 is expressed on activated T cells in coordination with other events, like shedding of CD62L and CCR7, leading to mobilization of these cells from secondary lymphoid organs.
In contrast, CCR7 directs immune cell homing to secondary lymphoid organs. This is true for T cells and for antigen-presenting cells, like dendritic cells. In the case of antigen-presenting cells, homing to secondary lymphoid organs allows these cells to interact with T cells in lymph nodes and the spleen, where conditions are optimal for T-cell activation.
We have shown that hypertension is associated with accumulation of splenic dendritic cells that produce copious amounts of IL-6, IL, and IL-1β, compatible with such a homing event in hypertension. Fontana V. de Faria A. DC isoketal-modified proteins activate T cells and promote hypertension. Kirabo A.
Renal denervation prevents immune cell activation and renal inflammation in angiotensin II-induced hypertension. Effector T cells, macrophages, natural killer cells, and platelets express CX3CR and home to sites where the CX3C fractalkine is expressed.
Mice lacking CX3CR1 develop reduced fibrosis compared with wild type mice when subjected to DOCA-salt hypertension. Furuichi K. Sakai N. Fractalkine and its receptor, CX3CR1, promote hypertensive interstitial fibrosis in the kidney.
Hypertens Res. Crossref PubMed Scopus 45 Google Scholar. Related to the function of vascular adhesion molecules and chemokines is the expression and function of matrix metalloproteinases MMPs. These degrade matrix, allowing migration of immune cells.
Barhoumi et al. recently showed that genetic deletion of MMP2 in mice completely prevents the elevation of blood pressure caused by ang II infusion. Fraulob-Aquino J. Mian M. Matrix metalloproteinase-2 knockout prevents angiotensin II-induced vascular injury.
Crossref PubMed Scopus 58 Google Scholar. Inflammasomes are multicomponent cytoplasmic complexes that promote cleavage of precursor to active forms of IL-1α,β, IL, and IL An in-depth discussion of the various subtype components of inflammasomes is beyond the scope of this review, but has been covered in depth elsewhere.
Schroder K. Inflammasome signaling and regulation of interleukin-1 family cytokines. Crossref PubMed Scopus 5 Google Scholar. Figure 2 Canonical inflammasome activation. Danger and pattern recognition pattern DAMPs and PAMPs molecules signal via Toll-like receptors to activate transcription of components of the nucleotide-binding oligomerization domain NOD -like receptor family pyrin domain containing 3 NLRP3 inflammasome and also pro-forms of interleukin IL -1 Pro-IL-1β , IL Pro-IL , and IL Pro-IL Cytokine signalling and these surface signals are transcriptionally mediated by nuclear factor kappa B NFκB.
These initial events are referred to as signal 1 or priming. Signal 2 requires additional triggering signals, including reactive oxygen species ROS , intracellular microcrystals, cellular potassium efflux, or lysosomal lysis. These lead to inflammasome assembly and recruitment of caspase 1, which in turn cleaves pro-forms to mature IL-1β, IL, and IL Inflammasome components NLRP3 and caspase activation and recruiting CARD are depicted.
Several studies have implicated the inflammasome and its products in hypertension. Serum levels of IL-1β have been reported to be elevated in humans with essential hypertension compared with subjects who had familial hypercholesterolemia without hypertension. Elisaf M.
Bairaktari E. Tsolas O. Siamopoulos K. Increased serum levels of interleukin-1beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients?. J Lab Clin Med. Abstract Full Text PDF PubMed Scopus Google Scholar. Franz S.
Pruss A. Preactivated monocytes from hypertensive patients as a factor for atherosclerosis?. Abstract Full Text Full Text PDF PubMed Scopus 39 Google Scholar. Norlander A. Elijovich F. Human monocyte transcriptional profiling identifies IL receptor accessory protein and lactoferrin as novel immune targets in hypertension.
Crossref PubMed Scopus 20 Google Scholar. Krishnan et al. showed that DOCA-salt hypertension in mice is associated with increased renal mRNA levels of ASC, nucleotide-binding oligomerization domain NOD -like receptor family pyrin domain containing 3, pro-caspase 1, and pro-IL-1β.
These investigators further showed that ASC-deficient mice develop blunted hypertension, had fewer renal macrophages, and developed less renal fibrosis compared with wild type mice in response to the DOCA-salt challenge. Likewise, a pharmacological inflammasome inhibitor, MCC, reduced hypertension in wild type mice.
Dowling J. Ling Y. As mentioned, uric acid crystals can activate the canonical inflammasome, and elevated uric acid levels have been implicated in hypertension. Recently, Zambom et al. have shown that lowering uric acid levels with allopurinol prevents inflammasome activation and lowers blood pressure in a model of hypertension caused by NO inhibition and high salt-feeding in rats.
Oliveira K.
Hypertension and inflammation access peer-reviewed chapter. Submitted: Hypertension and inflammation April Abd 06 Hypertension and inflammation Inflammagion 20 Hypertwnsion com customercare cbspd. Hypertension is a widely prevalent and a major modifiable risk factor for cardiovascular diseases. Power yoga sessions the inflammattion long list of anti-hypertension drugs and lifestyle modification strategies for blood pressure control, a large number of hypertensive patients fail to achieve adequate blood pressure control even when prescribed a combination of drugs from three or more classes. Thus, identifying and targeting of further mechanisms that underlie hypertension is decisive in alleviating burden of this disorder. In recent decades research have shown that perturbed immune system and inflammation contribute to hypertension.
Die sympathische Phrase